抗生素与我们的生活

2016-01-14 郑庆飞 科学网

1928年,英国微生物学家亚历山大·费莱明首次从青霉菌中发现了具有抗金黄色葡萄球菌活性的青霉素,从此进入了抗生素的黄金时代。在第二次世界大战中,青霉素作为一线药用抗生素拯救了成千上万人的性命,大大降低了由于伤口处细菌感染而引起的死亡几率,因此名声大噪的“神药”青霉素的价格曾一度比黄金还要昂贵。此后,赛尔曼·瓦克斯曼于1943年从链霉菌中分离得到了链霉素并首次系统性地定义了“抗生素”这个概念,作

1928年,英国微生物学家亚历山大·费莱明首次从青霉菌中发现了具有抗金黄色葡萄球菌活性的青霉素,从此进入了抗生素的黄金时代。在第二次世界大战中,青霉素作为一线药用抗生素拯救了成千上万人的性命,大大降低了由于伤口处细菌感染而引起的死亡几率,因此名声大噪的“神药”青霉素的价格曾一度比黄金还要昂贵。此后,赛尔曼·瓦克斯曼于1943年从链霉菌中分离得到了链霉素并首次系统性地定义了“抗生素”这个概念,作为青霉素后第二个进入临床使用的抗生素,链霉素拯救了无数结核病患者,使得中国古代望而生畏的“痨病”真正意义上地得到了有效治愈。然而,曾经立下“汗马功劳”的抗生素在近年来却屡屡遭受媒体和百姓的非议,“超级耐药菌”、“抗生素残留”、“抗生素滥用”等话题层出不穷,那么究竟什么是抗生素?抗生素真的有传说中的危害那么大吗?生活中应该如何正确使用抗生素?抗生素发展的未来又将如何?笔者将从自己的观点和研究经验出发,为大家解答这些问题。

在生活中,很多人认为具有“抗菌消炎”作用的药物就是抗生素。而目前科学上抗生素(antibiotics)较为完整和准确的定义是指由微生物(包括细菌、真菌、放线菌属)或高等动植物在生活过程中所产生的具有抗病原体或其它活性的一类次级代谢产物,能干扰其他生活细胞发育功能的化学物质。因此,从定义上我们可以知道抗生素是一类天然来源的化合物,因此1932年由格哈德·多马克发现能够有效抗菌的人工合成磺胺类药物——百浪多息,并非真正意义上的抗生素;另外,抗生素的功能也不仅仅局限于“抗菌消炎”,临床一线抗癌药物柔红霉素,放线菌素和博来霉素等都属于抗生素;基于天然产物化学骨架通过人工化学半合成进行结构修饰、改造的化合物也隶属于抗生素,其中包括基于青霉素结构骨架的氨苄西林、羧苄西林和基于红霉素结构骨架的罗红霉素和阿奇霉素等。因此,从定义上来看,大多数抗生素确实能够满足很多消费者的“纯天然来源”消费观,但是纯天然的对人体就完全无害吗?实际上,如何有效避免抗生素对人体的副作用,长久以来都是药物化学和生物化学科研工作者的重要研究课题之一,由于大多数病原微生物(支原体、衣原体、细菌、放线菌等)是与人体真核细胞构造不同的原核生物,基于这些显着的差异性,目前抗生素的研发一般都针对于原核生物所特有的细胞结构作为靶点,从而避免药物与人体真核细胞的相互作用。也正是因此,对于结构与人体细胞相近的真核病原微生物(真菌、原生动物等)、寄生虫和没有典型细胞结构的病毒,到目前仍然缺乏广谱、有效的抗生素药物。

实际上,到目前为止人们发现的不同来源、具有生物活性的天然抗生素已经超过两万余种,但是其中真正成药的却远没有这么多,大多数抗生素在基础研究阶段就被发现具有对实验动物的副作用,因此也就停止了后续的成药研究。我国科学家在早期寻找抗生素的研究中也取得了辉煌的成就,但正是由于当时的历史原因和难以避免的药物毒副作用,我国科学家所发现的抗生素并没有和青霉素、链霉素一样进入临床使用。早在1944年,上海丙康药厂任厂长和研究室主任汪猷先生(后任中国科学院上海有机所的所长)偶然听说世界上有人发现了一种特效的、从霉菌里培养出的抗生素(青霉素),于是他开始刻苦学习微生物学、发酵等方面的知识,决心在中国开拓出抗生素的研究道路。经过几年的实验研究,克服种种困难,他终于从橘子果皮上生长的一类霉菌中成功分离得到了一种新型的抗生素——“桔霉素”,并写了桔霉素的相关论文。该论文于1947年在美国著名杂志《科学》(Science)上发表后,美国一家通讯社从旧金山发出电讯,报道中国化学家汪猷制得一种新型抗生素的消息。汪猷先生后来又针对桔霉素进行了深入的研究,发表了十余篇论文,但是后续的研究却发现桔霉素具有显着的肾毒性,因此无法进入临床药用。因此,一种抗生素从被发现到真正作为一种药物被使用,需要经过漫长的研究周期和大量的经费投入,每一种今天我们正在使用的抗生素不但是大自然的无私馈赠,更是由无数科研工作者付出了无数汗水所换来的。另一方面,我们也可以看出,抗生素毒副作用的问题由来已久,毕竟自然界的生物生产抗生素的初衷是作为自身防御的武器,而不是为了给人类用来治病。直到今天,科研工作者仍然在努力试图通过使用构效关系解析、化学半合成、抗体偶联等方法解决抗生素副作用的问题,这仍是一个任重而道远的过程。

除了抗生素天然存在的毒副作用,抗生素耐药性问题是当今社会面临的重大问题之一。根据世界卫生组织(WHO)统计,感染类疾病是目前世界范围内威胁人类生命健康的第二大杀手。由于抗生素滥用等原因,临床耐药菌的不断出现使得这一现状更为严峻,多重耐药“超级细菌”的出现曾一度引起社会的恐慌,而目前新型抗生素的研发速度远慢于临床中耐药菌的产生速度,每当推出一种能够临床安全应用的抗生素,很快就能检测到对其耐药的病原菌,如此往复下去很可能造成最终对感染性疾病“无药可用”的境地。为什么抗生素滥用就会导致耐药菌的出现?“感冒了,硬挺着不吃药,就能防止自己身上出现耐药菌”,这样的观点又是否正确呢?抗生素的滥用的确是导致耐药病原体频频出现的直接原因,根据达尔文进化论的自然选择学说,由于遗传过程中的基因突变,具有不同基因型的病原菌同时生活在一个种群中,然而具有耐药基因型的病原菌需要表达耐药基因或改变自身正常的构造,因此在正常的生活条件下耐药菌的生长在整个种群中并没有优势,仅能以极低的比例存在;然而,当抗生素在这些病原菌的生长环境中出现时,本来处于生长优势的“野生型”病菌被大量杀死,而那些少量的“突变型”耐药病原菌则得到存活,由此大量繁衍生息成为庞大的耐药菌种群。在大自然漫长的进化过程中,有“矛”就必有“盾”,抗生素固然是大自然产生的有效武器,但是大自然也必然保留着相应的“破解方法”。科研工作者通过研究目前已经发现了数十类病原体耐受抗生素的抗性调控机制,能够有效应对环境中出现的不同类型的抗生素。分裂生长速度越快的病原体,基因突变率就越高,其耐药性产生的速度也就越快,因此生长、分离迅速的癌细胞和艾滋病病毒过快的耐药性产生同样也是目前世界范围内的重大科研难题之一。据统计,在人类使用抗生素之前和使用初期,世界范围内的耐药菌出现速度远远慢于当今,随着不同种类抗生素的不断开发,临床上耐药菌开始呈指数级地出现。这种现状是十分容易理解的,正如同宠物、农作物、观赏植物种类产生的速度在一直加快一样,由人类“插手”的“人工筛选”速度远远快于“自然筛选”,人类为了得到有利于自己生产、生活的新基因型物种,通过杂交、嫁接、转基因等方式大大加快了仅仅依靠基因突变而产生新物种的速度。而人们对于抗生素的滥用,正是在对耐药菌进行着无形的“人工筛选”。而如今世界范围内发达的交通运输,使得这些“人工筛选”得到的耐药菌可以快速传播;即使你得了病也坚持不用抗生素,体内确实没有“筛选”出大量的耐药菌,但是仍然有可能“躺枪”,因为世界上任何一个滥用抗生素的地区的患者身上的超级耐药菌都可能以“迅雷不及掩耳”的速度到达我们身边,而这些病原体一但感染了人体,将难以通过现有的临床药用抗生素进行治疗。因此,单靠社会上一两个人坚持不服用抗生素类药物,是根本不可能避免世界范围内抗生素耐药性问题的。但是话说回来,感冒了坚持不用抗生素,一点作用都没有吗?实际上,作用还是有一些的,因为对于一些类型的抗生素,人体自身也会将之作为半抗原并产生抗性(从而将该药物快速降解或使之失活),长期服用某些抗生素即使身体中的病原菌没有产生耐药性,人体自身也可能产生对于这类药物的耐受性。那么,得了病就不能吃药了吗?当然不是,得了病还是需要科学服药的,但是应该严格按照医嘱而不是自己随意在药店买药乱吃。造成“发热发炎”等感冒症状的原因很多,如果是由于流感病毒所引起的症状,使用针对细菌的抗生素(例如头孢、红霉素等)是完全没有效果的,不但不能有效治疗疾病,还会无形中帮助了耐药菌的产生;另外,不要长期只使用一种药物进行治疗,在产生相应的耐药菌之前就适当地更换使用其他种类的抗生素(类似于“鸡尾酒疗法”),有助于避免耐药菌的快速产生。

虽然知道了抗生素滥用所带来的危害,然而仍然有很多情况使我们防不胜防,这就不得不提一下“抗生素残留”的问题。近年来,媒体新闻不断揭露鸡蛋、牛奶和一些肉制品中的抗生素残留问题。实际上,农用抗生素使用已久,动物在生长过程中也难以避免感染病原菌,针对这些感染性疾病,人们研发了专门的兽用抗生素。而国内很多农产品企业为了经济利益和省时省力,无论动物是否患病都在饲料中加入了过量的抗生素,这些抗生素不但可能在家畜体内筛选得到耐药菌而产生“人畜交叉感染”,更可能在代谢过程中流入相应的农产品中而进一步被人类服用。因此,抗生素残留的问题根源正是农产品企业对于抗生素的滥用。值得指出的是,目前常用的抗生素(包括人用和兽用)对于人体本身的危害并不很大,少数毒副作用较大的抗生素(如具有耳毒性的链霉素和具有肾毒性的多粘菌素等)仅会在医院得到正确使用,而不会做成非处方类药物流入市场和药店;同时,科研工作者也正为消除、减弱这些抗生素的毒副作用做着努力。但是,滥用这些对于人体本身危害不大的抗生素所产生的有害影响却是十分长远和可怕的,当多重耐药性的超级病原体大规模爆发之时,很可能将会成为人类的末日。

虽然抗生素滥用的后果十分可怕,但是我们也完全不必杞人忧天和坐以待毙。首先,我们应该从每个人做起,不要感冒发烧后就“自己给自己开药”,应该遵循医嘱、科学合理用药;其次,我们应该呼吁社会中医药和食品行业不要乱用抗生素,毫无节制地滥用抗生素无异于人类在自掘坟墓。另一方面科研工作者也在日以继夜地做出着努力,除了挖掘新的抗生素资源,寻找和研究新型的抗生素作用机制也是一条有效的方案。其中,我国工作者做出了重要的贡献:去年的诺贝尔生理和医学奖颁发给了发现抗疟药青蒿素的我国科学家屠呦呦,和发现抗寄生虫药物阿维菌素的威日本科学家大村智和爱尔兰科学家廉·坎贝尔,屠呦呦在领奖时发表了题为《青蒿素的发现:传统中医给世界的礼物》的获奖感言,从我国和世界范围内的传统药材中进一步发现和挖掘新型抗生素将成为未来的研究潮流之一;去年,中国科学院上海有机化学研究所的研究人员还发现了一类古老的生物活性肽类抗生素——硫链丝菌素所具备的新型“双重”抗菌作用机制,这是目前发现的唯一一类能够主动作用于宿主(人体细胞)和胞内寄生菌,并在杀灭病原菌的同时提高宿主免疫防御能力的抗生素,改变了人们此前开发抗生素过程中试图完全避免其与人体细胞相互作用的传统思路,这样一种同时作用于宿主和寄生菌的独特抗菌作用模式比起传统药物的抗菌机制更不易产生耐药性,也将为未来抗感染药物的设计和研发给出新的启示。

总之,抗生素并不应该成为令人“谈虎色变”的洪水猛兽,而是大自然为我们提供的瑰宝。在抗生素诞生之前,人们只能依靠迷信活动和用烙铁烫发炎伤口的办法治疗感染性疾病,而今天抗生素的出现让人类的平均寿命大大延长。我们应该学会感恩,一包价格并不昂贵的抗生素不但凝聚着大自然的鬼斧神工,更凝聚着其背后一代代科研工作者的辛勤汗水。今天,我们的生活早已经离不开抗生素,但更不能让未来毁于抗生素的滥用。杜绝抗生素滥用,应该从我们每一个人做起。

作者单位:中国科学院上海有机化学研究所生命有机国家重点实验室

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=61453, encodeId=921a6145366, content=规范抗生素的应用很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 23:12:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58953, encodeId=c35b589539c, content=科普, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ba41656652, createdName=slicer, createdTime=Sun Jan 24 08:20:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58354, encodeId=a44a5835443, content=正规使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:34:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58355, encodeId=2d0a583552b, content=规范抗感, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:34:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58187, encodeId=d07d5818eda, content=必须赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLRP2D8sTDxkrGNjMqwyLUGd9Wbt6L0Yw9goia4ibPGLEx48lF9kvw86FKicbdWemTqujrf6K5WPIic8g/132, createdBy=69a11636814, createdName=ssummer, createdTime=Mon Jan 18 09:47:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57598, encodeId=59575e598a9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Jan 15 07:05:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57597, encodeId=7e445e597f1, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Jan 15 07:04:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57448, encodeId=6b6c5e448a6, content=必须解决滥用问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Jan 14 15:54:00 CST 2016, time=2016-01-14, status=1, ipAttribution=)]
    2016-01-27 文医生

    规范抗生素的应用很重要

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=61453, encodeId=921a6145366, content=规范抗生素的应用很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 23:12:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58953, encodeId=c35b589539c, content=科普, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ba41656652, createdName=slicer, createdTime=Sun Jan 24 08:20:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58354, encodeId=a44a5835443, content=正规使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:34:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58355, encodeId=2d0a583552b, content=规范抗感, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:34:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58187, encodeId=d07d5818eda, content=必须赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLRP2D8sTDxkrGNjMqwyLUGd9Wbt6L0Yw9goia4ibPGLEx48lF9kvw86FKicbdWemTqujrf6K5WPIic8g/132, createdBy=69a11636814, createdName=ssummer, createdTime=Mon Jan 18 09:47:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57598, encodeId=59575e598a9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Jan 15 07:05:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57597, encodeId=7e445e597f1, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Jan 15 07:04:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57448, encodeId=6b6c5e448a6, content=必须解决滥用问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Jan 14 15:54:00 CST 2016, time=2016-01-14, status=1, ipAttribution=)]
    2016-01-24 slicer

    科普

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=61453, encodeId=921a6145366, content=规范抗生素的应用很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 23:12:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58953, encodeId=c35b589539c, content=科普, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ba41656652, createdName=slicer, createdTime=Sun Jan 24 08:20:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58354, encodeId=a44a5835443, content=正规使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:34:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58355, encodeId=2d0a583552b, content=规范抗感, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:34:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58187, encodeId=d07d5818eda, content=必须赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLRP2D8sTDxkrGNjMqwyLUGd9Wbt6L0Yw9goia4ibPGLEx48lF9kvw86FKicbdWemTqujrf6K5WPIic8g/132, createdBy=69a11636814, createdName=ssummer, createdTime=Mon Jan 18 09:47:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57598, encodeId=59575e598a9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Jan 15 07:05:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57597, encodeId=7e445e597f1, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Jan 15 07:04:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57448, encodeId=6b6c5e448a6, content=必须解决滥用问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Jan 14 15:54:00 CST 2016, time=2016-01-14, status=1, ipAttribution=)]
    2016-01-19 忠诚向上

    正规使用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=61453, encodeId=921a6145366, content=规范抗生素的应用很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 23:12:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58953, encodeId=c35b589539c, content=科普, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ba41656652, createdName=slicer, createdTime=Sun Jan 24 08:20:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58354, encodeId=a44a5835443, content=正规使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:34:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58355, encodeId=2d0a583552b, content=规范抗感, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:34:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58187, encodeId=d07d5818eda, content=必须赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLRP2D8sTDxkrGNjMqwyLUGd9Wbt6L0Yw9goia4ibPGLEx48lF9kvw86FKicbdWemTqujrf6K5WPIic8g/132, createdBy=69a11636814, createdName=ssummer, createdTime=Mon Jan 18 09:47:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57598, encodeId=59575e598a9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Jan 15 07:05:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57597, encodeId=7e445e597f1, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Jan 15 07:04:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57448, encodeId=6b6c5e448a6, content=必须解决滥用问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Jan 14 15:54:00 CST 2016, time=2016-01-14, status=1, ipAttribution=)]
    2016-01-19 忠诚向上

    规范抗感

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=61453, encodeId=921a6145366, content=规范抗生素的应用很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 23:12:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58953, encodeId=c35b589539c, content=科普, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ba41656652, createdName=slicer, createdTime=Sun Jan 24 08:20:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58354, encodeId=a44a5835443, content=正规使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:34:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58355, encodeId=2d0a583552b, content=规范抗感, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:34:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58187, encodeId=d07d5818eda, content=必须赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLRP2D8sTDxkrGNjMqwyLUGd9Wbt6L0Yw9goia4ibPGLEx48lF9kvw86FKicbdWemTqujrf6K5WPIic8g/132, createdBy=69a11636814, createdName=ssummer, createdTime=Mon Jan 18 09:47:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57598, encodeId=59575e598a9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Jan 15 07:05:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57597, encodeId=7e445e597f1, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Jan 15 07:04:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57448, encodeId=6b6c5e448a6, content=必须解决滥用问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Jan 14 15:54:00 CST 2016, time=2016-01-14, status=1, ipAttribution=)]
    2016-01-18 ssummer

    必须赞!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=61453, encodeId=921a6145366, content=规范抗生素的应用很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 23:12:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58953, encodeId=c35b589539c, content=科普, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ba41656652, createdName=slicer, createdTime=Sun Jan 24 08:20:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58354, encodeId=a44a5835443, content=正规使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:34:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58355, encodeId=2d0a583552b, content=规范抗感, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:34:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58187, encodeId=d07d5818eda, content=必须赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLRP2D8sTDxkrGNjMqwyLUGd9Wbt6L0Yw9goia4ibPGLEx48lF9kvw86FKicbdWemTqujrf6K5WPIic8g/132, createdBy=69a11636814, createdName=ssummer, createdTime=Mon Jan 18 09:47:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57598, encodeId=59575e598a9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Jan 15 07:05:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57597, encodeId=7e445e597f1, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Jan 15 07:04:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57448, encodeId=6b6c5e448a6, content=必须解决滥用问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Jan 14 15:54:00 CST 2016, time=2016-01-14, status=1, ipAttribution=)]
    2016-01-15 wzf990214

    有意思

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=61453, encodeId=921a6145366, content=规范抗生素的应用很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 23:12:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58953, encodeId=c35b589539c, content=科普, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ba41656652, createdName=slicer, createdTime=Sun Jan 24 08:20:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58354, encodeId=a44a5835443, content=正规使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:34:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58355, encodeId=2d0a583552b, content=规范抗感, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:34:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58187, encodeId=d07d5818eda, content=必须赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLRP2D8sTDxkrGNjMqwyLUGd9Wbt6L0Yw9goia4ibPGLEx48lF9kvw86FKicbdWemTqujrf6K5WPIic8g/132, createdBy=69a11636814, createdName=ssummer, createdTime=Mon Jan 18 09:47:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57598, encodeId=59575e598a9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Jan 15 07:05:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57597, encodeId=7e445e597f1, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Jan 15 07:04:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57448, encodeId=6b6c5e448a6, content=必须解决滥用问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Jan 14 15:54:00 CST 2016, time=2016-01-14, status=1, ipAttribution=)]
    2016-01-15 wzf990214

    有意思

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=61453, encodeId=921a6145366, content=规范抗生素的应用很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4371683642, createdName=文医生, createdTime=Wed Jan 27 23:12:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58953, encodeId=c35b589539c, content=科普, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ba41656652, createdName=slicer, createdTime=Sun Jan 24 08:20:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58354, encodeId=a44a5835443, content=正规使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:34:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58355, encodeId=2d0a583552b, content=规范抗感, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:34:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58187, encodeId=d07d5818eda, content=必须赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLRP2D8sTDxkrGNjMqwyLUGd9Wbt6L0Yw9goia4ibPGLEx48lF9kvw86FKicbdWemTqujrf6K5WPIic8g/132, createdBy=69a11636814, createdName=ssummer, createdTime=Mon Jan 18 09:47:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57598, encodeId=59575e598a9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Jan 15 07:05:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57597, encodeId=7e445e597f1, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Jan 15 07:04:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57448, encodeId=6b6c5e448a6, content=必须解决滥用问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Jan 14 15:54:00 CST 2016, time=2016-01-14, status=1, ipAttribution=)]
    2016-01-14 xiaotaiyang1

    必须解决滥用问题

    0

相关资讯

J Exp Med:肺部细菌有助于调剂机体免疫系统

胃肠病学副教授Saurabh Mehandru领导进行了这项研究,结果表明,肺部细菌可有助于调节机体免疫功能,而过去民众一度认为肺部是没有细菌存在的。西奈山医学院的研究人员将研究结果发表在Experimental Medicine。这研究为探究微生物对肺部免疫功能的影响奠定了基础,也有助与研究用于预防肺和身体其它部位感染的鼻疫苗。 机体拥有数万亿对民众无害的细菌,这些细菌与人类共生且彼此互利。但目

2015尿路感染诊断与治疗中国专家共识

导 语:.临床中制定尿路感染的治疗方案应遵循《抗菌药物临床应用指导原则》。抗菌治疗方案不仅包括抗菌药物的选用品种、剂量、给药次数、给药途径、疗程等,还需要综合考虑病原菌、感染部位、感染程度和患者的生理、病理情况。 品种选择 抗菌药物品种的选用应根据病原菌种类及病原菌对抗菌药物的敏感性,即细菌药物敏感试验的结果而定。对临床诊断为尿路感染的患者应在开始抗菌治疗前,及时留取合格尿标本

中国人体内发现无敌细菌无视抗生素?作者辟谣

中国人体内发现对抗生素耐药性强“超级细菌”基因?近日,这样一种说法迅速传遍网络,难道“后抗生素”时代真的来了?这种“超级细菌”真的存在?文章的源头是一篇学术文章。11月18日,国际最专业、权威的医学杂志《柳叶刀》(The Lancet)的子刊《柳叶刀·传染病》发布了一则最新研究报告。研究发现,在中国人体内,发现了应对多黏菌素抗生素的MCR -1基因。研究结果出炉后,有舆论称,MCR- 1基因的出现

Lancet infect dis:动物饲养滥用抗生素后果已现:中国出现超级耐药细菌

多粘菌素目前仍是抗击革兰氏阴性菌的最后一道防线。如今,研究者们在中国的肉类食品样本以及住院的部分患者体内发现了一种能够抵抗这一药物的基因。更加令人恐慌的是,这一类基因存在于细菌的质粒中,可以轻易的在细菌之间传递。"这一发现具有深远的影响",来自澳大利亚"皇家布里斯班和女性医院"的医生,David L Paterson博士说到。 这一项由华南农业大学的动物医学学院的Yi-Yun Liu进行的研

“肝肾功能不全、孕妇儿童”用抗生素,需注意这些问题!

致谢来源:抗菌药物临床应用指导原则(2015版)  肾功能减退患者抗菌药物的应用 (一)基本原则 许多抗菌药物在人体内主要经肾排出,某些抗菌药物具有肾毒性,肾功能减退的感染患者应用抗菌药物的原则如下: 1.尽量避免使用肾毒性抗菌药物,确有应用指征时,严密监测肾功能情况。 2.根据感染的严重程度、病原菌种类及药敏试验结果等选用无肾毒性或